Genprex Inc. (NASDAQ: GNPX) announced the publication of data from its Acclaim-1 Phase 1 clinical trial in the journal Clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE